A. Horban

Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH S

R. Kaiser, J. Gatell, K. Ruxrungtham, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine

A. Lazzarin, F. Wit, R. Wood, 2001, AIDS.

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

B. Gazzard, C. Katlama, K. Ruxrungtham, 2004, The Lancet.

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

M. Moroni, F. Antunes, J. Montaner, 2003, AIDS.

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

B Clotet, J J Kastelein, F. van Leth, 2001, AIDS.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.